All posts
-
Press Coverage — January 6, 2023
AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
-
Press Coverage — January 6, 2023
C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer models
-
Press Releases — January 5, 2023
C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer models
-
Press Coverage — January 5, 2023
C2i Genomics and AzstraZeneca Successfully Evaluate Whole Genome-Based Residual Disease Test for Cancer
-
Press Coverage — January 5, 2023
AstraZeneca to Evaluate C2i Genomics’ Cancer Detection, Monitoring Platform
-
Press Coverage — January 5, 2023
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
-
Press Coverage — January 5, 2023
C2i Genomics extends collaboration with AstraZeneca following successful solid cancer testing
-
Press Coverage — January 5, 2023
AstraZeneca to Evaluate C2i Genomics’ Cancer Detection, Monitoring Platform
-
Press Releases — June 2, 2022
C2i Genomics and Karkinos Healthcare Partner to Bring AI-Powered Cancer Detection and Monitoring to India
-
Press Releases — April 6, 2022
C2i Genomics Launches C2inform MRD Test to Bring Distributed Cancer Monitoring to Cancer Centers Across Europe